Sector Update: Healthcare Stocks Flat to Lower Pre-Market; Vical Down 60% on Phase 3 Trial Results
Top Healthcare Stocks:
Healthcare shares are higher in pre-market trade. Vical Incorporated ( VICL ) is down 60% at $1.43 per share, at new 52-week lows, after it announced top-line results from a Phase 3 trial of Allovectin, an investigational intratumoral cancer immunotherapy, in patients with metastatic melanoma.
In other healthcare stocks news, DaVita HealthCare Partners ( DVA ) today announced that its Board of Directors has declared a two-for-one split of its common stock in the form of a stock dividend.
Stockholders of record on August 23, 2013 will receive two shares of the company's common stock for every share of common stock owned on the record date.
As of June 30, 2013, the company had 106.2 million shares of common stock outstanding which will increase to approximately 212.5 million shares after the stock split has been effected. DVA is flat at $114.35 pre-market.
Finally, Derma Sciences ( DSCI ) says Q2 sales were $18.1 million, below the Thomson Reuters mean for $19.95 million. Net loss was $0.43 per share, including items. The forecasts were for a $0.45 loss, usually less items. DSCI is flat at $14.09.